ACADIA Pharmaceuticals (NASDAQ:ACAD) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and Dyne Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
ACADIA Pharmaceuticals | 0 | 12 | 7 | 0 | 2.37 |
Dyne Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
ACADIA Pharmaceuticals presently has a consensus target price of $32.7647, suggesting a potential upside of 60.69%. Dyne Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 104.48%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than ACADIA Pharmaceuticals.
Insider and Institutional Ownership
93.5% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 59.4% of Dyne Therapeutics shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares ACADIA Pharmaceuticals and Dyne Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
ACADIA Pharmaceuticals | -63.92% | -40.35% | -34.72% |
Dyne Therapeutics | N/A | N/A | N/A |
Valuation & Earnings
This table compares ACADIA Pharmaceuticals and Dyne Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
ACADIA Pharmaceuticals | $339.08 million | 9.62 | $-235,260,000.00 | ($1.60) | -12.74 |
Dyne Therapeutics | N/A | N/A | N/A | N/A | N/A |
Dyne Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals.
Summary
Dyne Therapeutics beats ACADIA Pharmaceuticals on 5 of the 9 factors compared between the two stocks.